{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~25 mi. (Vienna, Austria, +192 more cities)
facility
Medizinische Universität Wien
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~25 mi. (Vienna, Austria, +89 more cities)
facility
Universitaetsklinikum Allgemeines Krankenhaus Wien-Klinik für Innere Medizin I, Abteilung Onkologie
biomarker
ER Positive, +2 more biomarkers
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~25 mi. (Vienna, Austria, +147 more cities)
facility
Allgemeines Krankenhaus der Stadt Wien ( Site 0567)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~25 mi. (Vienna, Austria, +130 more cities)
facility
Medical University Vienna ( Site 0054)
drug
BCG solution, +1 more drug
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
city
~25 mi. (Vienna, Austria, +93 more cities)
facility
Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)
drug
belzutifan, +1 more drug
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
city
~25 mi. (Vienna, Austria, +150 more cities)
facility
Medizinische Universitaet Wien ( Site 1903)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +2 more types
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~25 mi. (Vienna, Austria, +201 more cities)
facility
Medizinische Universitaet Wien /ID# 221446
drug
azacitidine, +1 more drug
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~25 mi. (Vienna, Austria, +145 more cities)
facility
Social Medical Center - Otto Wagner Hospital ( Site 0801)
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~25 mi. (Vienna, Austria, +197 more cities)
facility
Medizinische Universitaet Wien /ID# 240499
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
drug
azacitidine, +1 more drug
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
city
~25 mi. (Vienna, Austria, +165 more cities)
facility
Medizinische Universitaet Wien /ID# 220906
biomarker
del(11)(q10), +27 more biomarkers
drug
navitoclax, +1 more drug